Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen

Cindy Serdjebi (1) , Jean-François Seitz (2) , Joseph Ciccolini (3, 1) , Muriel Duluc (2) , Emmanuelle Norguet (2) , Frédéric Fina (4) , Bruno Lacarelle (5, 1) , L’houcine Ouafik (1, 4) , Laetitia Dahan (6, 2)

1 CRO2 - Centre de Recherches en Oncologie biologique et Oncopharmacologie
2 Service d'oncologie digestive et hépato-gastro-entérologie [Hôpital de la Timone - APHM]
3 SMARTc unit - Simulation & Modelling : Adaptive Response for Therapeutics in Cancer
4 Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM]
5 Pharmacocinétique Toxicocinétique - [Hôpital de la Timone - APHM]
6 TIMONE - Hôpital de la Timone [CHU - APHM]

Domains: Life Sciences [q-bio]; Cancer

Cindy Serdjebi, Jean-François Seitz, Joseph Ciccolini, Muriel Duluc, Emmanuelle Norguet, et al.. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Pharmacogenomics, 2013, 14 (9), pp.1047 - 1051. ⟨10.2217/pgs.13.93⟩. ⟨hal-01708020⟩